Marketing authorisation: approval to place a medicine on the market
A marketing authorisation (MA) is the approval a medicine needs before it is placed on the EU market, granted by a national authority or the Commission.
Also known as: MA, marketing authorization, product licence
4 min readUpdated
Reviewed by Gosia Luksza, CEO at Regunaut
At a glance
- Legal basis
- Article 6, Directive 2001/83/EC; Article 3, Regulation (EC) No 726/2004
- Granted by
- A national competent authority or the European Commission
- Assessment
- Up to 210 days, excluding clock-stops
- Validity
- Five years, then unlimited after one renewal
How it works
Article 6(1) of Directive 2001/83/EC states the rule: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authority of that Member State under the Directive, or an authorisation has been granted under Regulation (EC) No 726/2004. There are two kinds. A national authorisation is granted by one Member State's authority and is valid in that country only; a product reaches several countries through the mutual recognition or decentralised procedure, which produce a set of harmonised national authorisations. A Union authorisation is granted by the European Commission after an EMA assessment in the centralised procedure and is valid throughout the EU, and through corresponding decisions in Iceland, Liechtenstein and Norway.
An authorisation is granted to a named holder for a defined product: an active substance or combination in a given strength and pharmaceutical form, with its manufacturers, specifications, indications and product information. Those terms are fixed in the decision and its annexes, which include the summary of product characteristics, the labelling and the package leaflet. Strengths, forms and presentations added later belong to the same global marketing authorisation for the purposes of data protection. Under Article 26 of the Directive an application is refused where the benefit-risk balance is not favourable, therapeutic efficacy is insufficiently substantiated, the composition is not as declared, or the dossier does not meet the Directive's requirements.
Grant is the start of the obligations, not the end. The holder must keep the dossier in line with scientific and technical progress through variations, operate a pharmacovigilance system, report the dates on which the product is actually marketed, and ensure appropriate and continued supply. Under Article 24 of the Directive and Article 14 of the Regulation the authorisation is valid for five years and is renewed once on a re-evaluation of the benefit-risk balance, after which it is normally valid for an unlimited period. It lapses under the sunset clause if the product is not on the market for three consecutive years, and authorities can vary, suspend or revoke it on the grounds in Article 116. An authorisation does not settle price, reimbursement or patent questions, which are decided separately.
What goes wrong
Treating the authorisation date as the launch date, when national pricing, mock-up approval and serialisation still stand between the decision and the first pack; losing track of the conditions and post-authorisation commitments attached to the decision; letting the registered details drift from reality, for example a manufacturer or holder address that changed without a variation; assuming that a national authorisation covers another Member State; and missing the renewal or the marketing status notifications for a product that was authorised but never launched.
Timing
Day 0
Valid application; the assessment clock starts
Day 210
End of the assessment, not counting clock-stops
+30 to 67 days
National authorisations after MRP or DCP, or the Commission decision
Year 5 minus 9 months
Renewal application due
After renewal
Valid for an unlimited period, subject to the sunset clause
Article 17 of the Directive gives Member States 210 days from a valid application to complete a national procedure, and the CHMP has 210 days for its opinion in the centralised procedure; both exclude the clock-stops in which the applicant answers questions. The Commission decision follows a positive CHMP opinion within up to 67 days, and national authorisations follow within 30 days of the end of a mutual recognition or decentralised procedure. The renewal application is due nine months before the fifth anniversary of grant.
What teams do with it in Regunaut
One job in the platform that turn on Marketing authorisation, each part of a wider workflow.
What the 2026 EU pharma package changes
Under the new pharma package (not yet in force), marketing authorisations become valid for an unlimited period from grant by default, with five years only where validity is limited on safety grounds or the authorisation is granted in exceptional circumstances; see MA validity changes.
Marketing authorisation: common questions
What is a marketing authorisation?
It is the regulatory approval that allows a medicine to be placed on the market. In the EU, Article 6 of Directive 2001/83/EC prohibits marketing a medicinal product without one. The authorisation names the holder and fixes the product's composition, manufacturers, indications and product information, and any later change to those terms needs a variation.
Who grants marketing authorisations in the EU?
National competent authorities grant national authorisations, including those that result from the mutual recognition and decentralised procedures. The European Commission grants Union authorisations, valid in every Member State, on the basis of a scientific opinion from EMA's Committee for Medicinal Products for Human Use in the centralised procedure.
How long is a marketing authorisation valid?
Five years from grant. It can then be renewed on a re-evaluation of the benefit-risk balance, with the application due at least nine months before expiry, and once renewed it is valid for an unlimited period unless the authority requires one further five-year renewal on pharmacovigilance grounds. It ceases to be valid if the product is not marketed for three consecutive years.